Roth Capital Upgrades GeoVax Labs (NASDAQ:GOVX) to Strong-Buy

GeoVax Labs (NASDAQ:GOVX) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in a report issued on Tuesday, Zacks.com reports.

GOVX has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a report on Tuesday, July 2nd. Roth Mkm began coverage on shares of GeoVax Labs in a research note on Tuesday. They set a “buy” rating and a $20.00 price objective for the company.

GeoVax Labs Stock Performance

Shares of GOVX opened at $3.02 on Tuesday. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $10.24. The firm’s 50-day simple moving average is $2.12 and its two-hundred day simple moving average is $2.52.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. As a group, equities analysts expect that GeoVax Labs will post -7.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.